• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间歇性热量限制或低碳水高脂肪饮食治疗非酒精性脂肪性肝病——一项随机对照试验

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.

作者信息

Holmer Magnus, Lindqvist Catarina, Petersson Sven, Moshtaghi-Svensson John, Tillander Veronika, Brismar Torkel B, Hagström Hannes, Stål Per

机构信息

Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.

Unit of Gastroenterology and Hepatology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

出版信息

JHEP Rep. 2021 Feb 17;3(3):100256. doi: 10.1016/j.jhepr.2021.100256. eCollection 2021 Jun.

DOI:10.1016/j.jhepr.2021.100256
PMID:33898960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8059083/
Abstract

BACKGROUND & AIMS: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is weight reduction. Several diets have been proposed, with various effects specifically on liver steatosis. This trial compared the effects of intermittent calorie restriction (the 5:2 diet) and a low-carb high-fat diet (LCHF) on reduction of hepatic steatosis.

METHODS

We conducted an open-label randomised controlled trial that included 74 patients with NAFLD randomised in a 1:1:1 ratio to 12 weeks' treatment with either a LCHF or 5:2 diet, or general lifestyle advice from a hepatologist (standard of care; SoC). The primary outcome was reduction of hepatic steatosis as measured by magnetic resonance spectroscopy. Secondary outcomes included transient elastography, insulin resistance, blood lipids, and anthropometrics.

RESULTS

The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis (absolute reduction: LCHF: -7.2% [95% CI = -9.3 to -5.1], 5:2: -6.1% [95% CI = -8.1 to -4.2], SoC: -3.6% [95% CI = -5.8 to -1.5]) and body weight (LCHF: -7.3 kg [95% CI = -9.6 to -5.0]; 5:2: -7.4 kg [95% CI = -8.7 to -6.0]; SoC: -2.5 kg [95% CI =-3.5 to -1.5]. There was no difference between 5:2 and LCHF ( = 0.41 for steatosis and 0.78 for weight). Liver stiffness improved in the 5:2 and SoC but not in the LCHF group. The 5:2 diet was associated with reduced LDL levels and was tolerated to a higher degree than LCHF.

CONCLUSIONS

The LCHF and 5:2 diets were more effective in reducing steatosis and body weight in patients with NAFLD than SoC, suggesting dietary advice can be tailored to meet individual preferences.

LAY SUMMARY

For a person with obesity who suffers from fatty liver, weight loss through diet can be an effective treatment to improve the condition of the liver. Many popular diets that are recommended for weight reduction, such as high-fat diets and diets based on intermittent fasting, have not had their effects on the liver directly evaluated. This study shows that both a low-carb high-fat and the 5:2 diet are effective in treating fatty liver caused by obesity.

CLINICAL TRIALS REGISTRATION

This study is registered at Clinicaltrials.gov (NCT03118310).

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)的一线治疗方法是减轻体重。人们提出了几种饮食方案,它们对肝脏脂肪变性有不同的影响。本试验比较了间歇性热量限制饮食(5:2饮食法)和低碳水高脂肪饮食(LCHF)对减轻肝脏脂肪变性的效果。

方法

我们进行了一项开放标签的随机对照试验,纳入了74例NAFLD患者,按1:1:1的比例随机分为三组,分别接受为期12周的LCHF饮食、5:2饮食或肝病专家提供的一般生活方式建议(标准治疗;SoC)。主要结局是通过磁共振波谱法测量的肝脏脂肪变性减轻情况。次要结局包括瞬时弹性成像、胰岛素抵抗、血脂和人体测量指标。

结果

LCHF饮食和5:2饮食在减轻脂肪变性方面均优于SoC治疗(绝对降低值:LCHF:-7.2%[95%CI=-9.3至-5.1],5:2:-6.1%[95%CI=-8.1至-4.2],SoC:-3.6%[95%CI=-5.8至-1.5])和体重(LCHF:-7.3kg[95%CI=-9.6至-5.0];5:2:-7.4kg[95%CI=-8.7至-6.0];SoC:-2.5kg[95%CI=-3.5至-1.5])。5:2饮食和LCHF之间没有差异(脂肪变性方面P=0.41,体重方面P=0.78)。5:2饮食组和SoC组的肝脏硬度有所改善,但LCHF组没有。5:2饮食与低密度脂蛋白水平降低有关,且耐受性高于LCHF。

结论

对于NAFLD患者,LCHF饮食和5:2饮食在减轻脂肪变性和体重方面比SoC更有效,这表明饮食建议可以根据个人偏好进行调整。

简要概述

对于患有脂肪肝的肥胖者,通过饮食减肥可以有效改善肝脏状况。许多推荐用于减肥的流行饮食方案,如高脂肪饮食和基于间歇性禁食的饮食,尚未直接评估其对肝脏的影响。本研究表明,低碳水高脂肪饮食和5:2饮食在治疗肥胖引起的脂肪肝方面均有效。

临床试验注册

本研究已在Clinicaltrials.gov注册(NCT03118310)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/784ad395f65c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/ba89cdaa06fa/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/5cfc42698c0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/784ad395f65c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/ba89cdaa06fa/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/5cfc42698c0a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ff/8059083/784ad395f65c/gr2.jpg

相似文献

1
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.间歇性热量限制或低碳水高脂肪饮食治疗非酒精性脂肪性肝病——一项随机对照试验
JHEP Rep. 2021 Feb 17;3(3):100256. doi: 10.1016/j.jhepr.2021.100256. eCollection 2021 Jun.
2
Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.热量不受限制的低碳水化合物、高脂肪饮食与高碳水化合物、低脂肪饮食对2型糖尿病和非酒精性脂肪性肝病的影响:一项随机对照试验。
Ann Intern Med. 2023 Jan;176(1):10-21. doi: 10.7326/M22-1787. Epub 2022 Dec 13.
3
Macronutrient composition and its effect on body composition changes during weight loss therapy in patients with non-alcoholic fatty liver disease: Secondary analysis of a randomized controlled trial.非酒精性脂肪肝患者减肥治疗期间宏量营养素组成及其对体重变化的影响:一项随机对照试验的二次分析。
Nutrition. 2023 Jun;110:111982. doi: 10.1016/j.nut.2023.111982. Epub 2023 Feb 2.
4
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.12 周间歇性热量限制对比非酒精性脂肪性肝病患者常规护理的效果:一项随机对照试验。
Trials. 2023 Aug 2;24(1):490. doi: 10.1186/s13063-023-07444-4.
5
Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.限热量的地中海饮食和低脂饮食对非酒精性脂肪肝患者的脂肪酸状态的影响。
Nutrients. 2020 Dec 23;13(1):15. doi: 10.3390/nu13010015.
6
Evidence that supports the prescription of low-carbohydrate high-fat diets: a narrative review.支持低碳水化合物高脂肪饮食处方的证据:叙述性评论。
Br J Sports Med. 2017 Jan;51(2):133-139. doi: 10.1136/bjsports-2016-096491.
7
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD.运动对日本非酒精性脂肪性肝病男性患者肝脏脂肪变性和硬度的益处独立于体重减轻。
JHEP Rep. 2021 Feb 10;3(3):100253. doi: 10.1016/j.jhepr.2021.100253. eCollection 2021 Jun.
8
Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.超重和肥胖代谢功能障碍相关脂肪性肝病患者极低卡路里生酮饮食 8 周前后肝脂肪变性和纤维化的性别差异。
Nutrients. 2024 May 8;16(10):1408. doi: 10.3390/nu16101408.
9
Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.热量相同的动物蛋白或植物蛋白饮食可减少 2 型糖尿病患者的肝脏脂肪和炎症。
Gastroenterology. 2017 Feb;152(3):571-585.e8. doi: 10.1053/j.gastro.2016.10.007. Epub 2016 Oct 17.
10
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.限制蛋氨酸摄入可防止瘦素缺乏型肥胖小鼠的肝脂肪变性进展。
Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.

引用本文的文献

1
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.
2
Adaptation using IM Adapt of an evidence-based lifestyle intervention to support the management of metabolic-dysfunction associated steatotic liver disease among Hispanic/Latino adults.使用IM适应 对基于证据的生活方式干预措施进行调整,以支持对西班牙裔/拉丁裔成年人中与代谢功能障碍相关的脂肪性肝病的管理。
Front Public Health. 2025 Jul 25;13:1628845. doi: 10.3389/fpubh.2025.1628845. eCollection 2025.
3

本文引用的文献

1
Precision Nutrition-the Answer to "What to Eat to Stay Healthy".精准营养——“吃什么能保持健康”的答案。
JAMA. 2020 Aug 25;324(8):735-736. doi: 10.1001/jama.2020.13601.
2
Human postprandial responses to food and potential for precision nutrition.人类对食物的餐后反应和精准营养的潜力。
Nat Med. 2020 Jun;26(6):964-973. doi: 10.1038/s41591-020-0934-0. Epub 2020 Jun 11.
3
Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance.非酒精性脂肪性肝病与不同糖耐量人群的心血管疾病相关。
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.
呼吁将有风险的代谢功能障碍相关脂肪性肝炎的诊断率提高一倍。
Lancet Reg Health Eur. 2025 Jun 4;54:101320. doi: 10.1016/j.lanepe.2025.101320. eCollection 2025 Jul.
4
Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.非酒精性脂肪性肝病的药物治疗:当代治疗方法与未来展望
Int J Mol Sci. 2025 Jul 7;26(13):6518. doi: 10.3390/ijms26136518.
5
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.老年人脂肪性肝病:临床意义与未满足的需求
Nutrients. 2025 Jun 30;17(13):2189. doi: 10.3390/nu17132189.
6
Ketone metabolites in metabolic dysfunction-associated steatotic liver disease progression: optimizing keto-therapeutic strategies.代谢功能障碍相关脂肪性肝病进展中的酮类代谢产物:优化酮治疗策略
Am J Physiol Endocrinol Metab. 2025 Aug 1;329(2):E290-E301. doi: 10.1152/ajpendo.00178.2025. Epub 2025 Jul 7.
7
Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials.间歇性禁食策略及其对体重和其他心血管代谢危险因素的影响:随机临床试验的系统评价和网状荟萃分析
BMJ. 2025 Jun 18;389:e082007. doi: 10.1136/bmj-2024-082007.
8
Role of Fasting in the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review of Clinical Trials.禁食在非酒精性脂肪性肝病(NAFLD)管理中的作用:一项临床试验的系统评价
Cureus. 2025 May 16;17(5):e84259. doi: 10.7759/cureus.84259. eCollection 2025 May.
9
Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients.体重减轻对2型糖尿病和非酒精性脂肪性肝病患者胰岛素抵抗及肝脏健康的影响。
Med Sci Monit. 2025 Jun 16;31:e947157. doi: 10.12659/MSM.947157.
10
Prognostic value of atherogenic index of plasma on the all-cause and causes-specific mortality among patients with metabolic dysfunction-associated steatotic liver disease.血浆致动脉粥样硬化指数对代谢功能障碍相关脂肪性肝病患者全因死亡率和特定病因死亡率的预后价值。
Diabetol Metab Syndr. 2025 Jun 14;17(1):212. doi: 10.1186/s13098-025-01800-x.
Diabetes Metab Res Rev. 2020 Nov;36(8):e3333. doi: 10.1002/dmrr.3333. Epub 2020 May 31.
4
Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial.低碳水化合物饮食对非酒精性脂肪性肝病青少年肝脏脂质含量的影响:一项初步随机试验。
Pediatr Obes. 2020 Jul;15(7):e12630. doi: 10.1111/ijpo.12630. Epub 2020 Mar 4.
5
Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.非酒精性脂肪性肝病和纤维化与前瞻性研究中心血管事件风险增加相关。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2324-2331.e4. doi: 10.1016/j.cgh.2019.12.026. Epub 2019 Dec 27.
6
Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial.隔日禁食对非酒精性脂肪肝患者体重和血脂异常的影响:一项随机对照试验。
BMC Gastroenterol. 2019 Dec 18;19(1):219. doi: 10.1186/s12876-019-1132-8.
7
The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.可改变的风险因素对非酒精性脂肪性肝病长期结局的影响。
Aliment Pharmacol Ther. 2020 Jan;51(2):291-304. doi: 10.1111/apt.15580. Epub 2019 Nov 29.
8
Effects of Periodic Fasting on Fatty Liver Index-A Prospective Observational Study.周期性禁食对脂肪肝指数的影响:一项前瞻性观察研究。
Nutrients. 2019 Oct 30;11(11):2601. doi: 10.3390/nu11112601.
9
A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease.一项关于改良隔日热量限制改善非酒精性脂肪性肝病活动的有效性和依从性的随机对照试验。
Sci Rep. 2019 Aug 2;9(1):11232. doi: 10.1038/s41598-019-47763-8.
10
A carbohydrate-reduced high-protein diet improves HbA and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.低碳水化合物高蛋白饮食可改善 2 型糖尿病患者体重稳定时的 HbA 和肝脂肪含量:一项随机对照试验。
Diabetologia. 2019 Nov;62(11):2066-2078. doi: 10.1007/s00125-019-4956-4. Epub 2019 Jul 23.